COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients (AVA-CELL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01836536
Recruitment Status : Completed
First Posted : April 22, 2013
Last Update Posted : March 1, 2017
Information provided by (Responsible Party):
Center Eugene Marquis

Brief Summary:

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is an antiangiogenic treatment currently proposed to recurrent high grade glioma patients. Unfortunately some patients fail to respond to this treatment and finding biological factors allowing the discrimination between potential responders and non responders would be very helpful. As the immune system plays a key role in angiogenesis induction and maintenance in cancer, it could serve as a surrogate marker of angiogenesis in cancer patients.

The purpose of this study is to determine the influence of bevacizumab treatment on circulating immune cells in high grade glioma patients and to search for a link between the variation of these cells and the response to treatment.

Condition or disease Intervention/treatment Phase
Glioblastoma Glioma Drug: Bevacizumab standard of care Not Applicable

Detailed Description:

The following leucocyte subsets will be analyzed in whole blood before treatment and before cycles 3, 5 and 7:

  • Classical, intermediate, nonclassical and Tie2 expressing monocytes.
  • Regulatory T cells (Treg).
  • Myeloid Derived Suppressor cells (MDSCs) The variation of the absolute numbers (or relative percentages) of the cells in the blood of patients will be correlated to the response to treatment assessed according to the RANO criteria.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment
Study Start Date : September 2012
Actual Primary Completion Date : March 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
BEVACIZUMAB standard of care
Drug: Bevacizumab standard of care
Standard treatment associated with circulating leucocytes (blood samplings)
Other Name: Avastin

Primary Outcome Measures :
  1. blood cells populations [ Time Frame: up to 4 months ]
    Analysis of blood cells populations variation during treatment with bevacizumab. Last sampling planned before the 7th cycle of bevacizumab.

Secondary Outcome Measures :
  1. Cells variation and RMI response [ Time Frame: 6 weeks ]
    Relationship between variation of blood cells and RMI response after 6 weeks of treatment

  2. Survival [ Time Frame: Patients will be followed up from the date of randomization up to their death, assessed up to 100 months ]
    Link between variation of analyzed cellular population and survival.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically proved recurrent glioblastoma or anaplasic glioma,
  • Tumor recurrence documented by MRI at least 3 months after the end of radiotherapy or chemotherapy.
  • Patients for whom a treatment by bevacizumab is proposed by a multidisciplinary team staff.
  • Age ≥ 18.
  • Signed informed consent.
  • Affiliation to a social security coverage

Exclusion Criteria:

  • Known Hepatitis B or C or HIV.
  • Inclusion in another clinical trial.
  • Patient having received an anti-angiogenic therapy.
  • Pregnant or breast-feeding woman.
  • Person deprived of liberty or under guardianship or trusteeship or judicial protection
  • Inability to give informed consent
  • Person unable or unwilling to comply with the requirements of the protocol for geographical, social or psychological reasons.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01836536

Layout table for location information
Hôpital Avicenne
Bobigny, France, 93009
Center Eugene Marquis
Rennes, France, 35042
Sponsors and Collaborators
Center Eugene Marquis
Layout table for investigator information
Principal Investigator: Veronique QUILLIEN, MD Center Eugene Marquis

Layout table for additonal information
Responsible Party: Center Eugene Marquis Identifier: NCT01836536    
Other Study ID Numbers: AVA-CELL
First Posted: April 22, 2013    Key Record Dates
Last Update Posted: March 1, 2017
Last Verified: February 2017
Keywords provided by Center Eugene Marquis:
High grade glioma
Myeloid Cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors